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DIETARY CHOLESTEROLr TISSUE PHOSPHOLIPIDS, AND
PROSTACYCLIN PRODUCTION OF RAT AORTA
by
Mieko Hoshino Andress
Male Sprague-Dawley weanling rats were divided into 
three groups, a control (rat-chow and 5% corn oil), the
control diet plus cholesterol, and the control diet plus
both cholesterol and cholic acid. After four months the
animals were sacrificed and blood samples, along with
abdominal and thoracic aorta cross-sectional ring segments.
were collected. The serum cholesterol levels, fatty acid
compositions in the phospholipids (PL) of the aortic tissues
(thoracic and abdominal aorta tissues combined), and the
endogenous 6-keto-PGFla (stable metabolite of PGI2) 
production in thoracic and abdominal aortic tissues were
While serum cholesterol levels were highest in 
the rats fed a diet containing both cholesterol and cholic 
acid (p<0.01), dietary cholesterol alone did not raise the 
serum cholesterol level to a value greater than the control 
diet.
determined.
A marked reduction of arachidonic acid (AA) in PL of
the combined aortic tissues, and a reduction in endogenous 
6-keto-PGFla in the abdominal aortic tissue, were observed
in the rats fed dietary cholesterol, regardless of whether
or not cholic acid was added. By way of contrast, augmented
dietary cholesterol (alone or with cholic acid) had no
effect on the 6-keto-PGFla production in the excised
thoracic aortic tissues. The differences in the abdominal
and thoracic aorta tissues' response to augmented
cholesterol intake suggests important regional influences
(hemodynamic stress and elasticity) on PGI2 production. It
is of interest that rats fed cholesterol alone while not
demonstrating elevated serum cholesterol levels, had
markedly reduced AA in PL fatty acid composition, and
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Precursor and Biosynthesis of Arachidonic Acid
In 1960 Swedish investigators Bergstrom and Sjovall
succeeded in isolating two pure substances from seminal
fluids, prostaglandin E, (so named because of its good
solubility in ether) and prostaglandin F, soluble in
phosphate buffer (phosphate being spelled with "F" in
Swedish) (1,2). Since then a great number of prostanoid
compounds have been discovered. Naming has been by
alphabetical letter, beginning with the letter "A" and
ending with the most recently discovered member of the
family, prostacyclin, more commonly referred to as
Prostaglandin-12 (PGI2) (3).
Depending on the degree of unsaturation of the C20
chain, a distinction is made among the prostaglandins of the
one, two and three series, with one, two, and three double
bonds respectively (i.e. PGE1, PGD2, PGI3, etc). The series
two prostaglandins are currently considered to be the most
important in man (3).
1
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Linoleic acid, a fatty acid with 18 carbon atoms and
two double bonds, is modified by a process of desaturation
and chain-elongation into AA, a 20 carbon fatty acid with 4
This new compound then becomes the finaldouble bonds.
substrate for synthesis of the series two prostaglandins.
The main bulk of AA does not remain circulating as free
fatty acid, but rather is incorporated into the phospholipid
fraction of the cell membranes, usually in the 2nd position
of the glycerol moiety.
Since prostaglandin synthesis will not occur if the
fatty acid precursor remains esterified in the
phospholipids, free arachidonic acid must be made available
As soon as the integrity of theto serve as substrate.
phospholipid bilayer in the cell membrane is disturbed by
various stimuli, including simple friction of the membrane.
mediators of inflammation, or antigen-antibody immunological
reactions, cellular phospholipids become available to the
phospholipases, which are able to liberate AA (4).
Phospholipase A2 is the main enzyme which cleaves AA from
its 2nd position on the glycerol moiety of the phospholipids 
(5). However, AA can also be released by the combined action
of phospholipase C and diglyceride lipase (6).
Once AA is free, cyclooxygenase, present in the
microsomal fraction of most animal cells, transforms it into
the unstable prostaglandin endoperoxides, PGG2 and PGH2,
3
which lie at the crossroads of prostanoid metabolism. The
prostaglandin endoperoxides are then enzymatically
transformed into several possible prostaglandins including
two unstable products which act antagonistically to each
other, namely thromboxane A2 (TXA2) (7) and PGI2 (8,9). In
addition, the more stable PGE2, PGF2a, and PGD2 are
spontaneously metabolized from the endoperoxides. Before
the discovery of PGI2 and TXA2, PGE2 and PGF2a were
recognized as the primary products of arachidonic acid
metabolism (10).
Which compound will ultimately be formed by a
particular tissue under specific circumstances depends upon 
various factors such as the presence of certain cofactors, 
certain ions, and tissue specificity. In the platelets, the
prostaglandin peroxides are further metabolized into even
more unstable TXA2 by the enzyme thromboxane synthetase.
TXA2 is a very potent inducer of platelet aggregation and a
very powerful constrictor of arterial smooth muscle cells
(7).
On the other hand, the prostaglandin peroxides within 
the endothelial cells of vessel walls which do not possess 
thromboxane synthetase, are transformed into the unstable
PGI2 by the enzyme PGI2 synthetase. PGI2 is now recognized 
as the major product of AA metabolism in the arteries. In
contrast to TXA2 it is a very strong inhibitor of platelet
4
aggregation, and usually relaxes the vascular smooth muscle
cells (11).
One other pathway that needs to be mentioned is that 
found in leukocytes, platelets, and other tissues, where the 
enzyme lipoxygenase transforms AA into the leukotrienes 
(LTA4, LTB4, LTC4, LTD4, LTE4), so named because they were 
first isolated from polymorphonuclear leukocytes with three 
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The Function of Prostacyclin and Thromboxane
In 1970, Smith and Willis (13) demonstrated that under
the influence of thrombin, platelets release, among other
products, prostaglandins E and F. Later unstable
prostaglandin endoperoxides (14) and TXA2 (15) were isolated
from AA metabolites. TXA2 is one of the most potent
vasoconstrictors known and is a strong platelet aggregation
inducer (16,17).
It wasn’t until 1975 that TXA2's antagonist, PGI2 was
discovered. Moncada and his associates (8,9) began to study
vascular tissue in order to better understand homeostatic
plug formation. They showed that although TXA2 was not
formed in the vascular tissue, endoperoxide precursors were
transformed into some unknown substance which was an
inhibitor of platelet aggregation and much more potent than
either PGE1 or PGD2. The structure of this unknown substance
which was named PGX was elucidated. Later it was renamed
prostacyclin, abbreviated as PGI2.
PGI2 is a powerful and potent inhibitor of platelet 
adherence and aggregation, relaxes arterial blood vessels in 
vitro, and lowers the systemic arterial pressure through 
vasodilation (8). It has been suggested that under 
physiological disturbances, the stimulated platelets
7
adhering to the sites of vascular damage release TXA2, which
promotes further aggregation of platelets at those sites,
and causes localized vasoconstriction and platelet
adhesion. Also upon stimulation, the endothelial cells of
the healthy vessel walls increase PGI2 synthesis, thus 
limiting the process of platelet aggregation in the area of
vessel damage and thereby preventing thrombosis (18,19). 
Furthermore, when generated in sufficient quantity, PGI2 
penetrates to adjacent muscle layers to inhibit the 
vasoconstrictors produced by other agents in the blood (7).
The Relationship Between Atherosclerosis and PGI2
The above contrasts of metabolic sites and properties 
of TXA2 and PGI2 are very interesting, especially as they 
relate to the cardiovascular system, 
their antagonistic actions, it is realized that any 
dysfunction of vascular prostanoid metabolism may be an 
important factor contributing to vascular diseases
Since the discovery of
(20,21,22).
The following relationships suggest the role of PGI2
metabolism in the prevention of atherosclerosis.
1) Arteries of species in which atherosclerosis tends
to develop also exhibit a decrease in the production of
vascular PGI2 (23). In addition, human veins obtained from
8
surgical specimens, (human veins usually do not develop 
atherosclerosis) generate about eight times more PGI2 than 
human arteries (24). But in rats, animals that are notably 
resistant to spontaneous atherosclerosis, have arteries that
possess as high capacity to generate PGI2 as do the veins
(25).
2) In human studies, patients with atherosclerosis were
found to have impaired biosynthesis of PGI2 in the blood
vessels. Vessels obtained during surgery which demonstrated
different types of atherosclerotic lesions, such as fatty
streaks, fibrous intimal thickening, fibrous plaques, and
complicated lesions, showed significantly lower PGI2 
production than did morphologically unaltered arteries (26).
In addition, postmortem examinations suggest that a low 
production of PGI2 may lead to atherosclerotic lesions (27). 
3) Limited production of PGI2 in animals with
experimental atherosclerosis has been observed 
(32,33,34,35). These are discussed later.
However, it should be pointed out that the above 
observations seem to be in conflict with a more recent study
(28). They observed that the 
amount of PGI-M (2,3-dinor-6-keto-prostaglandin Fla, a major 
urinary metabolite of PGI2) excreted in a 24-hour urine
done by FitzGerald et al.
sample in patients with severe atherosclerosis was higher
This increasedthan that found in healthy male volunteers.
9
PGI2 metabolite in urine seems to contradict the reduced
capacity of PGI2 production by atherosclerotic vessels in 
vitro. The authors suggested that the capacity of vessels 
to produce PGI2 may far exceed the level of endogenous 
biosynthesis, so despite a reduced capacity for PGI2 
production, increased stimulus within atherosclerotic 
patients may have fostered an increase in PGI2 production.
Voss et al.(29) showed that plaque-containing thoracic 
vessels of rabbits with dietary induced atherosclerosis, 
produced more PGI2 than did the normal segments of the same 
aortic region. A similar characteristic was observed when
comparing healthy rabbits with rabbits in which
atherosclerosis had been induced. Those regions (aortic
arch and near the branching off of the abdominal aorta)
producing the most PGI2 in the healthy rabbits corresponded 
with the sites demonstrating the most severe atherosclerotic
changes in the experimental animals.
Regional Nature of Atherosclerosis
Atherosclerosis, whether in experimental animal models
or in human arteries, does not affect the arteries in a
uniform manner. The mechanism underlining the regional
development of atherosclerosis is uncertain. Arteries are
heterogenous in their functional requirements and undergo
10
remarkable biochemical and structural adaptations (30). For
example, along the course of the aorta, the pulse-pressure-
volume deformations are accommodated by a compliant and
highly elastic thoracic aorta. The progression of the
pulse-pressure-volume wave into the abdominal aorta region 
is augmented by reflection waves arising from the area of 
the renal artery branches and from the distal aorta at its 
bifurcation into the iliac arteries (31). Unlike the
thoracic aorta, the abdominal aorta has limited compliance. 
Consequently the mechanical wall stress in transporting 
blood is greater in the abdominal than in the thoracic
In man atherosclerosis develops earlier and is moreaorta.
florid in the abdominal than in the thoracic aorta (32).
Regional differences in mechanical wall stress may be
the basis for the greater PGI2 production in the abdominal
than in the thoracic aorta of rabbits as reported by Voss et
al.(29) Artery wall sensors of intraluminal pressure-volume
deformations are probably an endothelial cell function and
PGI2 is produced largely by these cells, 
endothelial cells by mechanical stress or atherosclerotic
Perturbation of
lesions appears to be accompanied by increased PGI2 
production. And the perturbations secondary to dietary
cholesterol-induced atherosclerosis in rabbits display 
regional variations in PGI2 production along the course of
the aorta (29).
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The Association Between Dietary Cholesterol and
Cardiovascular Disease
Atherosclerosis and coronary vascular disease are
associated with disturbances in lipid metabolism. However, 
the mechanism by which this occurs has not yet been
elucidated. Only a few cohort studies (33,34) have shown
that serum cholesterol concentrations are affected by diets
rich in cholesterol and saturated fat. Thus they have
suggested that dietary cholesterol may be associated with an
increased incidence of atherosclerosis and thrombosis.
As early as 1977, it was demonstrated in rabbits, that
atherosclerosis induced via dietary cholesterol, enhanced
TXA2 formation in the platelets while decreasing PGI2 
formation in the heart, mesenteric artery, and aorta (35).
A more recent study by Eldor et al.(36) suggests that
hypercholesterolemia inhibits the recovery of PGI2
production in the injured aorta thereby inducing
atherosclerosis. Fifty-five New Zealand white female
rabbits were divided into 4 groups, with the endothelium 
from the aortas of Groups I and II being removed by a
balloon catheter. Groups I and IV were fed on commercial
chow while Groups II and III were fed an egg supplemented
The serum cholesterol concentrations of Groups I anddiet.
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IV were lower than that of Groups II and III. PGI2 
production of randomly sampled aortic surface was stimulated
with AA and PGI2 was quantitated by radioimmunoassay for 
6-keto-PGFla. The quantities of exogenous PGI2 produced by
the reendothelialized area of the aortic luminal surface
were assayed, and the normocholesterolemic rabbits (Group-I) 
showed recovery with the time (increase in PGI2 production) 
but the hypercholesterolemic rabbits (Group-II) did not 
showed the recovery even seventy days after injury, 
synthesis by uninjured hypercholesterolemic rabbits (Group 
III) appeared to be less than that of controls (Group-IV), 
but was not statistically significant due to the large 
variance and small sample size.
In 1984, Mark et al.(37) using heart sections from 
special strains of mice (MRL/1 and MRL/n), demonstrated a 
negative correlation between serum cholesterol and PGI2
PGI2
production stimulated from AA, even though basal PGI2
production in buffer alone did not show any significant
dietary effects. In addition a positive correlation was
found between serum cholesterol and TXA2 production. Only 
MRL/1 mice developed vasculitic lesions regardless of diet. 
Yet only a diet that increased serum cholesterol led to
atherosclerosis.
An experiment by Wey et al.(38) suggests that normal
rats may be able to produce the same level of PGI2
13
regardless of whether the diet is high in cholesterol or
A group of control and a group of diabetic rats were 
both given a 0.5% cholesterol diet, 
aortas revealed that dietary cholesterol resulted in similar 
degrees of hyperlipidemia in both the rats with diabetes and




total serum cholesterol in the diabetic rats. Aortic
conversion of labeled AA to labeled 6-keto-PGFla in
cholesterol fed diabetic rats was significantly lower than
But where only endogenous 6-keto-PGFla wasother rats.
measured, the effects of dietary cholesterol were not
demonstrated in either normal or diabetic rats. But
regardless of diet, diabetic rats had a lower production of
6-keto-PGFla.
Relationship of HDL and LDL to PGI2 Metabolism
Epidemiological studies have shown a positive 
correlation between the plasma concentrations of LDL
cholesterol and the incidence of ischemic heart disease, and
at the same time a negative correlation with HDL cholesterol 
(39,40,41). To bridge the resultant dual hypotheses of the 
pathogenesis of atherosclerosis, 1) Effect of increased LDL
and decreased HDL concentrations, and 2) Disturbances of
PGI2 and TXA2 biosynthesis, the effects of LDL and HDL on
14
PGI2 biosynthesis have been studied by various 
investigators. The following is a sampling of the
findings.
Atherosclerotic arterial walls, have been shown to
generate large amounts of PGE2 but only small amounts of
PGI2 (42). A possible explanation for this reduction of PGI2 
could be that atherosclerosis damages the enzyme PGI2
synthetase but not cyclooxygenase. It has been known for
some time that PGI2 biosynthesis in porcine aortic 
microsomes is inhibited by 15-hydroperoxy-eicosatetraenoic 
acid (15-HPETE) and by other lipid peroxides since this
action was described at the same time PGI2 was first
discovered (9). While lipid peroxides always occur in human
plasma, their concentration in normal subjects is very low
(43).
In 1980, Szczeklik et al.(44) reported that PGI2
biosynthesis was decreased in rat aortic slices incubated
with LDL. The same was true of PGI2 biosynthesis induced by
sodium arachidonate in bovine coronary arteries. It was
proposed that atherogenic properties of LDL are associated
with inactivation of arterial PGI2 synthetase by lipid 
peroxides which are present in LDL, since lipid peroxides 
are not equally distributed among lipoproteins, 
contains the larger portion of these lipid peroxides, while 
HDL contains only marginal amounts.
LDL
In the same year, Beitz
15
and Forster (45) found a negative correlation between PGI2
synthetase activity in microsomal fraction of pig aorta and
the amount of LDL cholesterol in the incubation solution.
while at the same time there was a positive correlation with
HDL cholesterol.
However, in a later study, Szczeklik et al.(46)
presented evidence that the inhibitory peroxides in previous
studies occurred as a result of in vitro oxidation and in
fact may not take place inside the body. While in the 
presence of the antioxident, BHT, LDL from healthy subjects 
did not inhibit PGI2 synthesis. Nor did LDL from 11 out of 
15 coronary heart disease patients with concomitant type IIA 
familial hypercholesterolemia. However, LDL from the other
4 subjects, 2 with severe type IIA familial 
hypercholesterolemia, and 2 with coronary heart disease, 
inhibited PGI2 biosynthesis by more than 50 percent even 
though it was relatively free of lipid peroxides, 
they concluded that PGI2 inhibition is caused by some other 
factor than lipid peroxides.
Therefore
Beitz et al.(47) also concluded that because there was
a dose-dependent influence of LDL-peroxides from men on PGI2 
formation, but not from women, both the fatty acid pattern 
and the lipid class composition in the LDL must have an 
important influence on the biosynthesis of PGI2, rather than 
lipid peroxides being the sole inhibitor of PGI2
16
biosynthesis.
In 1982, Fleisher et al.(48) demonstrated that both
human and rat HDL induced the production of 6-keto-PGFla
from the cultured porcine aortic endothelial cells, though
rat HDL, which contains higher concentration of AA (54% in 
cholesteryl ester fatty acids), induced greater quantities
of 6-keto-PGFla than did human HDL. In comparison the
apoprotein part of HDL from both sources induced only small 
amounts of 6-keto-PGFla, while comparable stimulation by LDL
was not observed. This indicates that HDL may be providing
arachidonate substrate to endothelial cells for the
synthesis of PGI2.
Two years later, Pomerantz et al.(49) provided
additional support for the above hypothesis. In 24 hour
cultures of vascular smooth muscle cells, dose-related
increases of 6-keto-PGFla and PGE2 synthesis were associated
with human HDL and LDL but not with delipidated apoproteins
of HDL. Rat HDL which contains 2.5 times more cholesteryl
arachidonate than does human HDL, stimulated PGI2 and PGE2
synthesis to a greater extent than did human HDL. These
results suggest that AA from the lipoprotein is accessible 
to cyclooxygenase for PGI2 synthesis.
Specter's recent results (50) suggest again that the
process of PGI2 production is not specific for either of 
these two plasma lipoproteins, HDL and LDL, nor for free
17
arachidonic acid. But in endothelial prostaglandin
formation, free AA probably plays a more important role.
while HDL and LDL may not play as important of a role as has
been formerly thought, 
production in only small amounts during prolonged incubation 
(16 hours) of two different types of endothelial cell
Human HDL and LDL stimulate PGI2
cultures, human umbilical vein and bovine aortic 
endothelium. Compared with HDL and LDL, albumin-bound 
arachidonic acid produced PGI2 more rapidly. During HDL and
LDL incubation, the presence of albumin reduces the amount
of PGI2 production. Therefore PGI2 production from HDL or
LDL may occur to only a limited extent under physiological
conditions.
PURPOSE OF THIS STUDY
Since the discovery of prostacyclin (PGI2) and
thromboxane (TXA2), both of which are derived from a common
precursor, arachidonic acid (AA), through prostaglandin 
peroxides, their relationship to cardiovascular disease,
especially atherosclerosis, has been of great interest due 
to their antagonistic biological properties on platelet 
aggregation, the tone of the coronary arteries, and blood 
pressure (20,21,22). Even though it has been suggested that 
dietary cholesterol is atherogenic and raises the serum 
cholesterol concentration (33,34), the mechanism for this
has not been elucidated yet.
Thus the purpose of this research was to try to 
ascertain the relationship, if any, between dietary
cholesterol and PGI2 production in the arteries. Since
thoracic and abdominal aortas are different in elasticity 
and hemodynamic stress (30,31), PGI2 productions were 
compared in both thoracic and abdominal excised aortas from
young adult rats which were fed on cholesterol rich diets,
or on the standard rat chow diet. Also to see the
availability for basal PGI2 production in aortic tissue, 
fatty acid composition in phospholipid in the aortic tissues
18
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(thoracic and abdominal arotic tissues combined) were
measured.
The hypothesis that elevated serum cholesterol, induced




Three groups of male Sprague-Dawley weanling (21 days 
old) rats were placed on three different diets, for four 
months (Table 1). At the end of this period, the young adult 
rats were sacrificed and the thoracic and abdominal aortas.
along with blood samples were collected from each animal.
Endogenous aortic PGI2 production, total serum cholesterol.
and fatty acid composition of tissues were measured.
Table 1. Diet Composition
Diet 
(Group)
lab-chow corn-oil cholesterol cholic
95.0% 5.0% 0.0% 0.0%I
(control)
94.0% 5.0% 1.0%II 0.0%
93.75% 5.0% 1.0% 0.25%III
20
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6-Keto-PGFla Production by the Aorta;
An adaptation of the method described by Chan and Leith
(51) was used with the following modifications:
Three thoracic or abdominal aorta segments were 
incubated for 10 minutes at 37°C in 3ml tris buffer at PH
7.4. After the completion of the incubation, the buffer was
decanted from the artery segments and added to 6(Jjul of 4.8M 
formic acid in 4ml polypropylene tubes, capped and stored at 
-30°C for radioimmunoassay (RIA). The aorta segments were 
dried in a 100°C oven, after two acetone extractions had
been made, to obtain the fat free dry weight (ffdw). The
6-keto-PGFla was expressed as ng per mg ffdw as an
estimation of the endogenous PGI2 production.
RIA of 6-keto-PGFla:
The RIA of 6-keto-PGFla was an adaptation of a
procedure described by Lewis and associates (52) for the RIA
of PGE2. Standard 6-keto-PGFla was obtained from Upjohn
Diagnostics and the rabbit antibodies to 6-keto-PGFla were
obtained from Seragen Inc. The following reagents were
used.
1) Assay Buffer (Phosphate buffer):
50mM phosphate, 0.1% gelatin, and 0.5% thimerosal (as 
preservative) at a PH of 7.3.
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2) Polyethylene Gylcol(PEG):
250g/liter PEG molecular weight 6000-7500 Daltons stock 
solution was prepared in deionized water.
3) Standard 6-keto-PGFla:
Standard 6-keto-PGFla was purchased from the Upjohn
It was reconstituted and diluted to lOOng/ml.Company.
This is a stock standard. Dilutions were made for the
standard curve with b through g serving as working
standards for the curve determination (Table 2).












1,0000.1ml (lOOul) standard 
0.5ml of dilution a 
0.5ml of dilution b 
0.4ml of dilution c 
0.5ml of dilution d 
0.5ml of dilution e 








4) Radio labeled 6-keto-PGFla:
6-keto-PGFla [5,8,9,11,12,14,15,?H(N)] with a specific
activity of 120Ci/mM was purchased from New England
lOOpl (ljuCi) was diluted to 10ml with assayNuclear.
23
buffer for use in the assay.
5) Anti-Serum:
Rabbit anti-serum to 6-keto-PGFla (titer 1:45000) was
The dried anti-serum waspurchased from Seragen, Inc.
dissolved in 20ml of assay buffer as directed by
Seragen, Inc.
6) Scintillation Fluid:
Modified Bray*s solution was prepared as follows:
7.0g 2,5-diphenyloxazole
0.3g 1,4-cis 2-(4-Methyl-5-Phenyloxazolyl) benzene
100.Og naphthalene
dissolved in 1000ml of p-dioxane
All tubes were run in duplicate in 12 x 75mm
polypropylene test tubes according to the protocol in Table 
3. After the addition of antisera, the tubes were vortexed 
and incubated for a minimum of sixteen hours at 4°C. At the
end of the incubation period, the tubes were placed in an 
ice bath and SOOpl of PEG was then added to each tube, 
except for the total count tubes, and vortexed for 10
The tubes were then centrifuged for thirty minutes 
at 3500 RPM at 4°C. This centrifuging was done within thirty 
minutes after the addition of PEG. The supernatants, with
seconds.
the exception of the total count ones, were removed, and the
precipitates were redissolved in 1ml of deionized water and
vortexed vigorously until completely redissolved. The
24
dissolved precipitate was then counted in 10ml of modified 
Bray's solution for a minimum of ten minutes.
Table 3. Protocol for the radioimmunoassay of 6-keto-PGFla 
(all quantities expressed as ^ul)
Anti- jGlo- PEG 
body bulin
Tube Assay *a Tracer 
BufferNo.
Total counts lf2 
Buffer Blank 3,4 




200 100 200 500
100 100 100 200 500
7-18 100 100 100 200 500
19-etc 100 100 100 200 500
where (*a) is either standard or sample.
The order of addition of reagents does not matter, except 
the antibody should be added to a homogenous solution of 
the other added reagents.
PEG should be added after the 16 hour incubation period.
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Calculations for 6-keto-PGFla in samples;
The following methods were used to calculate the
standard curve and unknowns:
1) Average counts per minute for each set of duplicates.
2) Subtract the average blank count from each average
count.
3) Calculate percent bound (%B).
%B = (average net count) / (average net total count)
4) The normalized percent bound (%B/B0) for each standard
and sample was calculated using the following formula:
%B/B0 = %B of standard or sample x 100 
%B of "O" standard
5) Concentration of 6-keto-PGFla in each sample was 
calculated from the regression line (53). 
line ; Y = aX + b
X=log(x) ; where x is concentration of 6-keto-PGFla 
i.e. 500,250r100,50,25f10 for standards.
Y=ln(P/(100-P)) ; where P=B/BO x 100
26
Serum Cholesterol Determination:
Procedure as described for use of kit by Sigma.
1) Centrifuge blood collected from rat, with heparin at 
2000 rpm for 20 minutes and separate plasma.
2) To cuvettes labeled either BLANK, STANDARD, or with ID-#
of a rat, add 0.002ml of water, Cholesterol Aqueous
standard 50 mg/ml, 100 mg/ml, 200 mg/ml or 400mg/ml,
or serum from rats respectively.
3) To each cuvette, add 1.0ml of cholesterol assay solution
and mix by inversion.
4) Incubate cuvettes at 37°C for 15 minutes.
5) After setting the colorimeter to zero by using BLANK,
read the absorbance of STANDARD, and samples at 500nm.
6) Calculate each total serum cholesterol by using the
regression line calculated from STANDARD.
27
Arterial Tissue Phospholipid Determination:
Lipids were extracted from arterial tissues (thoracic
and abdominal aortic tissues combined) by a
chloroform-methanol solvent as described by Bligh and Dyer 
(54). The lipid extract was dried under nitrogen and
redissolved in hexane. The phospholipids were separated by
silicic acid column chromatography (55) and the fatty acid
methyl esters formedr by methanol-boron trifluoride as
described by Morrison and Smith (56). The quantity of AA and
other fatty acids were estimated by gas-liquid 
chromatography (G.L.C.) of the methyl esters and were 
reported as percent of total acids.
Specificity of G.L.C.
Varian model 3700 Gas Chromatograph Column 
10% SP2330 on 100/120 Supelcoport 
Injection T = 220°C 
T = 230° C
Temperature programmed from 155°C to 215°C
Detector
RESULTS
The serum cholesterol levels, phospholipid fatty acid
composition in aortic tissues (thoracic and abdominal aortic
tissues combined), and the endogenous 6-keto-PGFla
production in thoracic and abdominal aorta tissues were
compared in three diet groups of male Sprague-Dawley rats
that had been on the diets for four months. (See Table 1)
Animals in Group-II, receiving 1% cholesterol plus the 
control ration, did not show a significant increase in serum
cholesterol levels compared to those in the control group 
(Group-I). However, the addition of 0.25% cholic acid to the
1% cholesterol ration (Group-Ill) did result in a 
significant elevation of serum cholesterol (Table 4).
Both dietary cholesterol alone and the combination of
cholesterol with cholic acid produced a marked reduction in 
20:4w6 fatty acid composition of the total phospholipid 
fraction isolated from the aortic tissue lipids, 
reduction of 36% and 44% for groups II and III respectively 
was statistically significant (See Table 5). However no 





After ten minutes incubation of thoracic and abdominal
rings in Tris buffer, the 6-*keto-PGFla in the solution was
measured (Tables 6, 7). In the abdominal aorta tissue,
6-keto-PGFla production was reduced by 42% and 35% for 
Groups II and III respectively. The 13% reductions in 
6-keto-PGFla production in the thoracic aorta tissue for 
both Groups II and III were not statistically significant.
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I (5)* 89.8 + 2.6
II (8)* n.s. **106.1 ± 8.5
III (8)* 255.6 + 29.4 p<0.01 **
*) Number of animals per group in parentheses.
**) Analysis variance followed by Dunnett's procedure 
for the statistical comparison of mean values for 
groups II or III, compared to Group I, the control.
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Table 5. Fatty Acid Analysis of Aorta Total Phospholipids
fatty acid (%)
16:0 18:0Group 18:1 18:2 20:4
w6w9 w6
I (5)* 23.6+1.5 14.1+1.4 19.5+1.1 21.2+2.2 19.4+1.4
II (8)* 31.4+1.5 19.1+1.8 20.2+0.8 16.8+2.6 12.5+1.9**
III(8)* 31.0+2.9 21.3+3.4 20.5+2.0 16.4+3.0 10.8+3.0***
*) number of animals per group in parenthesis 
**) p<0.05 compared to Group-I 
***) p<0.01 compared to Group-I
Analysis of variance followed by Dunnett's 
Procedure.
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6-Keto-PGFla Production in Rat Thoracic 
Aorta Segments Incubated for 10 min. in 
Tris Buffer (0.05m) at PH 7.4
Table 6.
6-keto-PGFla 
(ng/mg dry weight of 
tissue + S.E.)Group
I (5)* 17.3 + 0.8
II (8)* 15.1 + 2.3 n.s. **
III (8)* 15.0 + 0.8 n.s. **
*) Number of animals per group in parentheses.
**) Analysis variance followed by Dunnett's procedure 
for the statistical comparison of mean values for 
groups II or III, compared to Group I, the control.
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6-Keto-PGFla Production in Rat Abdominal 
Aorta Segments Incubated for 10 min. in 
Tris Buffer (0.05m) at PH 7.4
Table 7.
6-keto-PGFla 
(ng/mg dry weight of 
tissue + S.E.)Group
23.1 + 3.1I (5)*
p<0.05 **13.3 + 1.2II (8)*
p<0.05 **15.0 + 2.1III (8)*
*) Number of animals per group in parentheses.
**) Analysis variance followed by Dunnett's procedure 
for the statistical comparison of mean values for 
groups II or III, compared to Group I, the control.
Discussion
Serum cholesterol is regarded as a major factor in the
development of coronary heart disease, although the
mechanism for this association is poorly understood. Our
approach to elucidating this problem was to investigate the
effect of dietary cholesterol on PGI2 biosynthesis, since
PGI2 production by arterial endothelium has been suggested
as one mechanism responsible for thrombo-resistance of the
endothelial surface of blood vessels (8,9). Dietary induced
hypercholesterolemia inhibits the recovery of PGI2
production in injured rabbit's aorta (36) and in the heart
tissue of mice (37). Both of the above studies measured PGI2
production by incubation of tissues in mediums containing
AA. Our study and an earlier reported preliminary study (57)
measured only endogenous synthesis of PGI2. The 36% and 44% 
decreases in 20:4w6 of groups II and III respectively for 
the abdominal aorta tissue would suggest a decrease in 
available substrate for PGI2 production, although it does 
not rule out a decrease in enzyme activity brought about by
the cholesterol containing diet.
The preliminary study (57) reported a decrease in PGI2
34
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production in the rat thoracic aorta tissue. The current
study however was not able to demonstrate such a dietary
cholesterol effect. This may be explained by a shorter time
period for the dietary treatment. Our experience has been
that the abdominal aorta is more active in PGI2 production
than is the thoracic aorta. This difference may be due to a
greater hemodynamic stress in the abdominal than in the
thoracic aorta wall (30f31). A large wall stress may be
accompanied by a labile cell membrane which is highly
responsive to a manipulation of dietary cholesterol and
thereby affects PGI2 production.
It is of interest that even though Group II animals did
not have a significant increase in serum cholesterol, they
did show, along with Group III, a marked decrease in
abdominal aorta PGI2 production. This suggests that serum
cholesterol per se is not as important as dietary effects on
In support of this, Spector et al.(6)the artery tissue.
have shown that endothelial cell cultures experience no
toxicity when incubated for 18 hours with LDL in 
concentrations up to 250jug/ml cholesterol and conclude that 
plasma lipoprotein may not play an important role in
endothelial PGI2 formation. Thus the cardiovascular disease
processes associated with abnormal cholesterol metabolism
may be mediated through an arterially reduced PGI2 metabolic
capacity.
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